Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Summer Street Posts Q4
Tweet Send to a Friend
Summer Street analyst Jim Molloy reiterated a Buy rating and $650 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE